OraSure Technologies, Inc. (OSUR)
Company Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally.
It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services.
In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing.
Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Country | United States |
| Founded | 2000 |
| IPO Date | Nov 12, 1986 |
| Industry | Health Care Equipment & Supplies |
| Sector | Health Care |
| Employees | 785 |
| CEO | Stephen Tang |
Contact Details
Address:
150 Webster St Bethlehem, Pennsylvania 18015-1338 United States | |
| Phone | 610 882 1820 |
| Website | orasure.com |
Stock Details
| Ticker Symbol | OSUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001116463 |
| CUSIP Number | 68554V108 |
| ISIN Number | US68554V1089 |
| Employer ID | 36-4370966 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Scott Gleason | Senior Vice President of Investor Relations and Corporate Communications and Interim Chief Financial Officer |
| Agnieszka M. Gallagher J.D. | Executive Vice President, General Counsel, Chief Compliance Officer and Secretary |
| Kathleen Gallagher Weber | President of Molecular Solutions |
| Carrie Eglinton Manner | President, Chief Executive Officer and Director |
| Michele Marie Miller | Senior Vice President, Chief Accounting Officer, Controller and Assistant Secretary |
| David A. Rappaport C.F.A., CFA | Senior Vice President Corporate Development, Strategy and Integration |
| Amy Steigerwalt | Vice President of Human Resources |
| Lisa Nibauer | President of Diagnostics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 9, 2022 | 8-K | Current report |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 6, 2022 | 3 | Initial statement of beneficial ownership of securities |
| Jun 2, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 26, 2022 | 8-K | Current report |
| May 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| May 23, 2022 | EFFECT | Notice of Effectiveness |